All In Biotech

Drug Trial Radar · NCT07077434

A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid Tumors

A Phase 1 Open-Label, Multi-Center Study to Evaluate Pharmacokinetics, Safety and Tolerability of Navlimetostat (BMS-986504) in Japanese and Chinese Participants With Advanced Solid Tumors With Homozygous MTAP Deletion

Last checked: Nov 20, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Oct 15, 2025

Primary completion

Jan 19, 2027

Study completion Jan 19, 2027

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jul 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability and drug levels of Navlimetostat (BMS-986504) in participants with advanced solid tumors.

Conditions

  • Advanced Solid Tumors

Interventions

  • BMS-986504Drug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Plasma Concentration (Cmax) of BMS-986504Time frame: Up to approximately Day 64
  2. Time to Reach Maximum Plasma Concentration (Tmax) of BMS-986504Time frame: Up to approximately Day 64
  3. Area Under Curve (AUC) of BMS-986504Time frame: Up to approximately Day 64
  4. Mean Elimination Half-life (T-HALF) of BMS-986504Time frame: Up to approximately Day 64
  5. Apparent Total Body Clearance (CLT/F) of BMS-986504Time frame: Up to approximately Day 64
  6. Apparent Volume of Distribution During the Terminal Phase (Vz/F) of BMS-986504Time frame: Up to approximately Day 64

Locations

12 sites in 2 countries. Site status is shown where the registry gives one.

  • Beijing Cancer hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Recruiting

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China · Recruiting

  • Peking University Shenzhen Hospital

    Shenzhen, Guangdong, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Recruiting

  • The First Affiliated Hospital of Xinxiang Medical University

    Xinxiang, Henan, China · Recruiting

  • Shandong Cancer Hospital

    Jinan, Shandong, China · Recruiting

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

  • Kanagawa cancer center

    Yokohama, Kanagawa, Japan · Recruiting

  • Shizuoka Cancer Center

    Sunto-gun, Shizuoka, Japan · Recruiting

  • National Cancer Center Hospital

    Chuo-ku, Tokyo, Japan · Recruiting

  • The Cancer Institute Hospital of JFCR

    Koto-ku, Tokyo, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.